Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Thrombosis and Haemostasis

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1615755PMID 11372675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conjectures and Refutations on the Mode of Action of Heparins

  1999influential reference
• Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action

  1998cited by this paper
• Fucoidan, as Heparin, Induces Tissue Factor Pathway Inhibitor Release from Cultured Human Endothelial Cells

  1998cited by this paper
• Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.

  1997cited by this paper
• The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.

  1997cited by this paper
• Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.

  1996influential reference
• Human Ryudocan from Endothelium-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor (*)

  1996cited by this paper
• The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin

  1995cited by this paper
• Two Receptor Systems Are Involved in the Plasma Clearance of Tissue Factor Pathway Inhibitor in Vivo(*)

  1995cited by this paper
• Tissue factor pathway inhibitor and the revised theory of coagulation.

  1995cited by this paper
• Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.

  1995cited by this paper
• Antithrombin III Affinity Dependence on the Anticoagulant, Antiprotease, and Tissue Factor Pathway Inhibitor Actions of Heparins

  1995cited by this paper
• TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.

  1995cited by this paper
• Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen

  1995cited by this paper
• Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.

  1994influential reference
• Heparin/low molecular weight heparin and tissue factor pathway inhibitor.

  1993cited by this paper
• Protamine Neutralization of the Release of Tissue Factor Pathway Inhibitor Activity by Heparins

  1993cited by this paper
• Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

  1993cited by this paper
• The present status of tissue factor pathway inhibitor.

  1992cited by this paper
• Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin.

  1992cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides.

  1984cited by this paper

• Elevated tissue factor pathway inhibitor delays thrombin generation in COVID-19 but is not associated with clinical outcomes

  2025cites this paper
• Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

  2022cites this paper
• The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.

  2016cites this paper
• The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin

  2016cites this paper
• Surveillance biologique des malades sous héparine ou sous fondaparinux

  2014cites this paper
• The anticoagulant and antithrombotic mechanisms of heparin.

  2012cites this paper
• Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

  2012cites this paper
• The contribution of tissue factor pathway inhibitor to thrombin generation in children receiving unfractionated heparin.

  2011cites this paper
• Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity

  2011cites this paper
• Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.

  2009cites this paper
• Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin

  2009cites this paper
• Pharmacological strategies for inhibition of thrombin activity.

  2008cites this paper
• Biomarkers and Coagulation Tests for Assessing the Biosimilarity of a Generic Low‐Molecular‐Weight Heparin: Results of a Study in Healthy Subjects With Enoxaparin

  2008cites this paper
• [Pharmacology of heparins and direct anticoagulants].

  2008cites this paper
• Pharmakologie der Heparine und der direkten Antikoagulanzien

  2008influential citation
• Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.

  2008cites this paper
• [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].

  2008cites this paper
• Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.

  2007cites this paper
• Fixed dosage of low‐molecular‐weight heparins causes large individual variation in coagulability, only partly correlated to body weight

  2006cites this paper
• Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.

  2006cites this paper
• Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities.

  2006cites this paper
• Tissue factor pathway inhibitor in childhood nephrotic syndrome

  2006cites this paper
• The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

  2005cites this paper
• Heparin and Low Molecular Weight Heparins in Clinical Cardiology

  2005cites this paper
• Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss

  2005cites this paper
• From heparins to factor Xa inhibitors and beyond

  2005cites this paper
• The ‘precautionary principle’ as a guide for future drug development

  2005cites this paper
• Biochemical and Pharmacologic Rationale for Synthetic Heparin Polysaccharides

  2005cites this paper
• Chromogene Methode zur funktionellen TFPI-Bestimmung

  2005cites this paper
• High-dose Intravenous Dalteparin Can be Monitored Effectively Using Standard Coagulation Times

  2005cites this paper
• LETTERS TO THE EDITOR: Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment

  2005cites this paper
• Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke

  2004cites this paper
• Antimetastatic effect of tinzaparin, a low‐molecular‐weight heparin

  2003cites this paper
• Local tissue factor pathway inhibitor release in the human forearm

  2003cites this paper
• Low‐Molecular‐Weight Heparins: Are they all the Same?

  2003cites this paper
• Antithrombotic agents under flow conditions

  2003cites this paper
• Pharmacodynamic Properties of the Low Molecular Weight Heparin, Tinzaparin: Effect of Molecular Weight Distribution on Plasma Tissue Factor Pathway Inhibitor in Healthy Human Subjects

  2003cites this paper
• The coagulation system as a target for experimental therapy of human gliomas

  2003cites this paper
• Emerging concepts in thromboprophylaxis

  2002cites this paper
• Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH

  2002cites this paper
• Comparative Effects of Unfractionated Heparin and Low Molecular Weight Heparin on Vascular Endothelial Cell Tissue Factor Pathway Inhibitor Release: A Model for Assessing Intrinsic Thromboresistance

  2002cites this paper
• Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

  2002cites this paper
• Molecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma

  2001cites this paper
• Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent

  2001cites this paper